TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00891540

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ropivacaine 0.5%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ropivacaine 0.2%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Isotonic NaCl
Study: NCT00591318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftriaxone
Description: 2 grams of ceftriaxone given daily, Monday to Friday, excluding major holidays, for a total of 40 doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 50 cc of normal saline, daily, Monday through Friday, except for major holidays, for a total of 40 normal saline infusions.
Study: NCT04431921

Intervention type: DIAGNOSTIC_TEST
Intervention: Functional capacity
Description: Six minute walk test used assessment of functional capacity. For respiratory function mouth pressures, for cognitive functions MoCA scale and for pain assessment pain threshold and tolerance test assessed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Functional capacity
Description: Six minute walk test used assessment of functional capacity. For respiratory function mouth pressures, for cognitive functions MoCA scale and for pain assessment pain threshold and tolerance test assessed.
Study: NCT04694924

Intervention type: OTHER
Intervention: standard of care
Description: No other procedures than those performed during the usual care for prostate cancer patients will be done. No study medication will be provided as part of participation.~Clinical outcomes will be reported via predefined electronic forms, integrated into the electronic health record (EHR). Patient-reported outcomes will be collected electronically.~All treatment decisions will be made at the discretion of the investigator or treating physician.
Study: NCT00856414

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A
Description: 20U, up to two injections administered intramuscularly into the glabella (2 in each side of the corrugators and 1 in the procerus)
Study: NCT01839604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9150
Description: Intravenous infusion over 3 hours.
Study: NCT04166799

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mepitel Film
Description: Mepitel® Film is a thin, soft and conformable transparent film dressing with Safetac®, offering protection for vulnerable skin.
Study: NCT00647270

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: Pre-filled syringe. See arm for more detail

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pre-filled syringe. See arm for more detail

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: Pre-filled syringe. See arm for more detail
Study: NCT00528554

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laser acupuncture
Description: laser acupuncture according to traditional chinese medicine criteria, energy dosage 1J/point, average of 8 points to be treated, once daily during chemotherapy course

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: placebo laser acupuncture
Description: laser acupuncture according to traditional chinese medicine criteria, average of 8 points to be treated, once daily during chemotherapy course
Study: NCT04076098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline Hydrochloride
Description: Administration of Periocline gel into the periodontal pockets will be carried out until it overflows the pockets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Minocycline Hydrochloride
Description: Administration of Periocline gel into the periodontal pockets will be carried out until it overflows the pockets
Study: NCT02619383

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Description: The treatment comprised 40 daily hyperbaric sessions, 5 days a week, in a multiplace hyperbaric chamber (HAUX-Life-Support GmbH). Each session consisted of 90 minutes of exposure to 100% oxygen at 2 ATA with 5 minutes air breaks every 30 minutes and 1 meter per minute compression and decompression.
Study: NCT00229515

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: abciximab followed by implantation of bare metal stent
Description: Patients will receive infusion of abciximab at standard regimen before undergoing intervention for STEMI and then bare metal stent implantation in the culprit lesion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: abciximab and Sirolimus eluting stent
Description: Patients will receive abciximab infusion at standard regimen followed by implantation of sirolimus-eluting stent in the culprit lesion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tirofiban and bare metal stent
Description: Patients will receive tirofiban infusion at high loading dose followed by standard infusion for 18-24 hours and subsequently they will be treated with bare metal stent implantation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tirofiban and sirolimus-eluting stent
Description: Patients will receive tirofiban infusion at high loading dose followed by standard infusion for 18-24 hours and subsequently they will be treated with sirolimus-eluting stent implantation
Study: NCT02135003

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patient-selected care buddy
Description: Patient-selected Care buddy intervention: In addition to standard of care, pre-ART patients randomized to this arm were requested to choose a care buddy who was aware of the patient's HIV infection and resided in the same household or in close proximity. Care buddies attended at least two HIV health education sessions similar to those provided to study participants. Information on HIV, and the importance of adhering to scheduled clinic visits and to prescribed medications will be emphasized. Buddies were requested to remind participants to take their prophylactic treatments, and remind them of clinic appointments
Study: NCT04139889

Intervention type: DIAGNOSTIC_TEST
Intervention: Confocal Laser Endomicroscopy
Description: Confocal laser microendoscopy (CLE) as a new non-invasive imaging technique can be used for optical biopsy, which can perform real-time microscopic information of tissue in vivo at cellular level with resolutions up to 1μm and magnifications up to 1000 times. CLE is now being increasingly used with very promising results in gastroenterology, especially in the diagnostic investigation of Barret's esophagus, stomach cancer, colorectal cancer and various lesions of the biliary tract. With an intravenous injection of fluorescein, probe-based CLE (pCLE: GastroFlex probe with the Cellvizio laser system, Mauna Technologies, Paris, France) allows us to view the interstitial spaces, cells, and small capillaries in a window of 240 μm and to a depth of 60 μm.

Intervention type: DIAGNOSTIC_TEST
Intervention: Confocal Laser Endomicroscopy
Description: Confocal laser microendoscopy (CLE) as a new non-invasive imaging technique can be used for optical biopsy, which can perform real-time microscopic information of tissue in vivo at cellular level with resolutions up to 1μm and magnifications up to 1000 times. CLE is now being increasingly used with very promising results in gastroenterology, especially in the diagnostic investigation of Barret's esophagus, stomach cancer, colorectal cancer and various lesions of the biliary tract. With an intravenous injection of fluorescein, probe-based CLE (pCLE: GastroFlex probe with the Cellvizio laser system, Mauna Technologies, Paris, France) allows us to view the interstitial spaces, cells, and small capillaries in a window of 240 μm and to a depth of 60 μm.

Intervention type: DIAGNOSTIC_TEST
Intervention: Confocal Laser Endomicroscopy
Description: Confocal laser microendoscopy (CLE) as a new non-invasive imaging technique can be used for optical biopsy, which can perform real-time microscopic information of tissue in vivo at cellular level with resolutions up to 1μm and magnifications up to 1000 times. CLE is now being increasingly used with very promising results in gastroenterology, especially in the diagnostic investigation of Barret's esophagus, stomach cancer, colorectal cancer and various lesions of the biliary tract. With an intravenous injection of fluorescein, probe-based CLE (pCLE: GastroFlex probe with the Cellvizio laser system, Mauna Technologies, Paris, France) allows us to view the interstitial spaces, cells, and small capillaries in a window of 240 μm and to a depth of 60 μm.
Study: NCT04169932

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD20 CAR-T
Description: The maximum dose was determined according to the dose escalation test. Based on the number of CART cells per kg body weight which was proved to be safe and effective, all the subjects were treated with one single dose of CD20 CART cells per treatment course. The dose escalation test was designed to evaluate the four dose levels of CD20-CART (1 × 10 \^ 6 cells/kg,2 × 10 \^ 6 cells/kg,4 × 10 \^ 6 cells/kg,8 × 10 \^ 6 cells/kg).
Study: NCT02720029

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pH/impedance monitor
Description: Placement of pH/impedance monitor via the nasogastric route with monitoring for 24 hours, followed by removal.
Study: NCT03236155

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: opioid pain pills
Description: patient will receive their pain pill prescription

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: opioid pain pills
Description: patient will receive their pain pill prescription
Study: NCT02990624

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: PUVA
Description: 36 sessions of psoralen-ultraviolet A, divided as 3 sessions weekly

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: PUVA
Description: 36 sessions of psoralen-ultraviolet A, divided as 3 sessions weekly
Study: NCT02704390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORADUR®-Methylphenidate
Description: ORADUR®-Methylphenidate is available in three dosage forms, 22 mg, 33 mg or 44 mg. Subjects will continue to receive ORADUR®-Methylphenidate at the previously determined optimal dose for 24 months.
Study: NCT00388583

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Split, Inactivated, Trivalent Influenza Vaccine
Description: 0.1 mL, Intradermal

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Split, Inactivated, Trivalent Influenza Vaccine
Description: 0.5 mL, Intramuscular
Study: NCT04441580

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CADe colonoscopy using GI Genius device
Description: We wanted to compare the diagnostic yield obtained by using CADe colonoscopy to the yield obtained by the standard colonoscopy (SC) in a FIT-positive screening population.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CADe colonoscopy using GI Genius device
Description: We wanted to compare the diagnostic yield obtained by using CADe colonoscopy to the yield obtained by the standard colonoscopy (SC) in a FIT-positive screening population.
Study: NCT02583217

Intervention type: DRUG
Intervention: Ketamine
Description: To compare ketamine+propofol versus remifentanyl+propofol to maintain good laryngeal mask insertion conditions

Intervention type: DRUG
Intervention: remifentanyl

Intervention type: DRUG
Intervention: propofol

Intervention type: DRUG
Intervention: propofol
Study: NCT00448097

Intervention type: DRUG
Group type: OTHER
Intervention: cetuximab
Description: No verifiable data available, PI relocated

Intervention type: DRUG
Group type: OTHER
Intervention: docetaxel
Description: No verifiable data available, PI relocated
Study: NCT00463606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-335 and rosuvastatin calcium
Description: ABT-335 135 mg in combination with rosuvastatin calcium 5 mg administered orally, once daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-335
Description: ABT-335 135 mg monotherapy administered orally, once daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosuvastatin calcium
Description: Rosuvastatin calcium 5 mg monotherapy administered orally, once daily for 12 weeks
Study: NCT01922648

Intervention type: PROCEDURE
Intervention: Blood sample
Description: An extra volume of blood is obtained, with prior consent, when phlebotomy is required for another unrelated clinical reason.

Intervention type: PROCEDURE
Intervention: Blood sample
Description: An extra volume of blood is obtained, with prior consent, when phlebotomy is required for another unrelated clinical reason.

Intervention type: PROCEDURE
Intervention: Blood sample
Description: An extra volume of blood is obtained, with prior consent, when phlebotomy is required for another unrelated clinical reason.
Study: NCT02707653

Intervention type: DRUG
Group type: OTHER
Intervention: Misoprostol
Description: 400 mcg sublingual misoprostol
Study: NCT04040348

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Approximately 100 million cells allogeneic hMSC
Description: Umbilical cord-derived, allogeneic hMSC administered intravenously at a dose of approximately 100 million cells per infusion.
Study: NCT01929122

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Control Meals and Snacks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cooked Navy Bean Powder Meals and Snacks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rice Bran Meals and Snacks
Study: NCT04006171

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: C type natriuretic peptide
Description: Serum level of CNP in PCOS and healthy women

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: C type natriuretic peptide
Description: Serum level of CNP in PCOS and healthy women
Study: NCT02583217

Intervention type: DEVICE
Intervention: laryngeal mask

Intervention type: DEVICE
Intervention: laryngeal mask
Study: NCT04043741

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: stretching exercises :single knee to chest (15 reps x 3 sets) double knee to chest(15 reps x 3 sets) strengthening exercises: extension exercises (15 reps x 3 sets)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sustain Pressure
Description: Sustain Pressure (Number of repetition and hold according to trigger point chronic level)~+ Hot pack 10 to 15 minutes + Active muscle stretching exercise (10 repetition twice daily)
Study: NCT03890666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol eMDPI DS
Description: Albuterol sulfate electronic multidose dry powder inhaler (Albuterol eMDPI) DS with 4 component devices:~* Device 1: Albuterol eMDPI~* Device 2: Albuterol eMDPI Patient-facing smart device application (App)~* Device 3: DHP Cloud solution)~* Device 4: Provider-facing dashboard (dashboard)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albuterol
Description: Standard of care albuterol-administering rescue inhaler
Study: NCT03339856

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Selective retina therapy
Description: The selective retina therapy (SRT) is a laser treatment to the retina using the R:GEN device (Lutronic, Goyang-si, South Korea).~Laser energy began at 80 µJ and was increased in 5-10 µJ intervals until the optimal energy delivery was confirmed by the RFD system. Following confirmation, the optimal laser energy was applied to fluorescein leakages. If the energy was indeed optimal at leakage points, laser shots were administered around the leakages. If the energy was not optimal at the leakage points, laser energy was again increased in 5-10 µJ increments until optimal energy delivery.
Study: NCT02884232

Intervention type: PROCEDURE
Intervention: Nasofibroscopy
Study: NCT04191993

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty
Description: Surgical intervention designed to replace arthritic joint with artificial implant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total hip arthroplasty
Description: Surgical intervention designed to replace arthritic joint with artificial implant
Study: NCT00050778

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Interferon beta-1a
Description: Interferon beta-1a 44 microgram (mcg) subcutaneously 3-times weekly for 36 months.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alemtuzumab 12 mg
Description: Alemtuzumab 12 milligram per day (mg/day) was given by intravenous infusion on 5 consecutive days during the first month and on 3 consecutive days at months 12 and 24 (the latter at the treating physicians' discretion if the cluster of differentiation 4+ \[CD4+\] T-cell count was \>=100\*10\^6 cells per liter).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alemtuzumab 24 mg
Description: Alemtuzumab 24 mg/day was given by intravenous infusion on 5 consecutive days during the first month and on 3 consecutive days at months 12 and 24 (the latter at the treating physicians' discretion if the CD4+ T-cell count was \>=100\*10\^6 cells per liter).
Study: NCT00131053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirarubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-asparaginase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Study: NCT00585598

Intervention type: OTHER
Intervention: replacing supralaryngeal airway with ET tube
Description: changing tube in trauma bay
Study: NCT02935426

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: n-butyl cyanoacrylate and 2-octyl cyanoacrylate
Description: used in cyanoacrylate group

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 5-0 Polytetrafluoroethylene (PTFE) suture
Description: used in suture group
Study: NCT03712371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chitosan
Description: The starting dose for Chitosan is 500mg twice a day, the second dose level is 1000mg twice a day, the third dose level is 1500mg twice a day, and the fourth dose level is 2000mg twice a day. Each dose level lasts for 28 days.
Study: NCT03629314

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational pamphlet arm
Description: Educational pamphlets will be provided to review and questionnaire will be provided to complete before and after review of the pamphlet
Study: NCT02872506

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti TNF
Description: Patients are admitted to day hospital with blood test less than 7 days. In the absence of contraindications, hydrocortisone infusion 200 mg will be conducted for 15 minutes followed by anti-TNF treatment infusion over 2 hours for the first three sessions. The following infusions of anti-TNF therapy will be on the same terms without hydrocortisone, every 4 to 8 weeks, in doses of 5-10mg/kg. Adverse effect most frequently reported was URTI. The most serious adverse reactions, were a reactivation of hepatitis B, congestive heart failure, serious infection, serum hypersensitivity reactions, blood diseases, systemic lupus erythematosus / lupus-like syndrome, demyelinating disorders, hepatobiliary metabolism disorders. The QOL will be assessed by IBDQ score at the inclusion visit before the first infusion and at 6 months.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ileocecal resection
Description: The operation is performed by laparoscopy or laparotomy. Hospital stay is on average 6 days. Preparation for the intervention is sometimes required 3 weeks to 1 month before the procedure to avoid risk situations.The main risk of the intervention is the anastomotic fistula. This risk of anastomotic leakage mainly concerns malnourished patients operated within the context of abdominal sepsis (abscess). An assessment protocol of post-operative pain, every 3 hours, is now well codified in routine surgery. The QOL will be assessed by the IBDQ score before surgery and at 6 months.
Study: NCT02568891

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: multispecies probiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matrix
Study: NCT04583137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocain
Description: Layngeal direct fiberoptic examination transnasaly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocain
Description: Layngeal direct fiberoptic examination transnasaly
Study: NCT02791568

Intervention type: PROCEDURE
Intervention: Ultrasound Scan
Description: The research exam is expected to take 30 minutes for blood flow assessments

Intervention type: PROCEDURE
Intervention: Ultrasound Scan
Description: The research exam is expected to take 30 minutes for blood flow assessments

Intervention type: PROCEDURE
Intervention: Ultrasound Scan
Description: The research exam is expected to take 30 minutes for blood flow assessments

Intervention type: PROCEDURE
Intervention: MRI Scan
Description: MR imaging will take approximately 30 minutes.

Intervention type: PROCEDURE
Intervention: MRI Scan
Description: MR imaging will take approximately 30 minutes.

Intervention type: PROCEDURE
Intervention: MRI Scan
Description: MR imaging will take approximately 30 minutes.

Intervention type: DRUG
Intervention: Ferumoxytol
Description: A subset of subjects will complete MRI imaging with ferumoxytol as a contrast agent at the 24-28 week visit. A nurse will administer ferumoxytol in a hospital triage with pulse and blood pressure monitoring and fetal heart monitoring. The pharmacy will prepare the infusion and deliver to triage. Subjects will arrive at the obstetric triage unit for ferumoxytol injection three days prior to their scheduled ferumoxytol MRI study. In the triage, the nurse will obtain baseline vital signs and fetal heart rate. The IV Ferumoxytol infusion will be 30 minutes and atients will be monitored at 5 to 15-minute intervals. Three days after the ferumoxytol infusion, at 24-26 weeks gestation, subjects will have blood/urine collected, undergo a 30 minute ultrasound, a 30 minute MRI, an adverse event review, and medical record review. The MRI scanning procedure will be conducted at WIMR and will last approximately 30-60 minutes.
Study: NCT04741126

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manually assisted cough technique
Description: Manually assisted cough technique will be given for four weeks. 10 to 12 repetitions of manually assisted cough technique with rest will be given in one minute 3 to 4 time of repetition in a 1 set. The result of the peak cough flow meter and incentive spirometer will be check pre and post only.3 sets will be given in one session and 2-time session will be recommended per day. The session will be given three days in a week. The Result of the Peak Cough flow meter and incentive spirometer will be check pre and post only.